13 research outputs found
TRaCS, computational algorithm to determine tissue specific alloreactive putative peptide minor histocompatibility antigens (pmHA).
<p>Whole exome sequencing of cryopreserved donor and recipient DNA was performed, with an average coverage of 90x. The variable <b><i>n</i></b> refers to the number of nsSNP<sub>GVH</sub> and <b><i>m</i></b> to pmHA. The variable <b><i>m</i></b> along with protein tissue expression level was then analyzed in MATLAB to determine T cell responses.</p
Cox proportional hazards model for cumulative GVHD (N = 47 of 73 evaluable) association with simulated organ specific T cell counts.
<p>Cox proportional hazards model for cumulative GVHD (N = 47 of 73 evaluable) association with simulated organ specific T cell counts.</p
Effect of alloreactivity operator on T cell vector .
<p>Successive iterations (<i>t</i>, <i>t+1 etc</i>.) modify the vector to . In this simplified model, <i>mHA</i><sub><i>x</i></sub><i>-HLA</i> only binds <i>TC</i><sub><i>x</i></sub> and so on. Matrix below represents a single iteration <i>t</i>.</p
Matrix illustrating the relative effect of antigen binding affinity on the T cell clonal interaction between different clones.
<p>Successive cells in each row of the matrix calculate the effect of <i>TC</i><sub><i>i</i></sub> on T cell being studied, <i>TC</i><sub><i>x</i></sub>. This generates a weighting factor, α, which modulates the impact of population of <i>TC</i><sub><i>i</i></sub> on the growth of <i>TC</i><sub><i>x</i></sub>.</p
Cox proportional hazards model for cumulative grade 2–4 acute and moderate to severe chronic GVHD (N = 39 of 73 evaluable) association with simulated organ specific T cell counts (expressed in 1000’s).
<p>Cox proportional hazards model for cumulative grade 2–4 acute and moderate to severe chronic GVHD (N = 39 of 73 evaluable) association with simulated organ specific T cell counts (expressed in 1000’s).</p
Exome sequencing and peptide results by donor type (n = 77).
<p>Exome sequencing and peptide results by donor type (n = 77).</p
Modeling the effect of Treg on effector T cell growth.
<p>Modeling the effect of Treg on effector T cell growth, red curve, <i>r</i> reduced at 21st iteration from -1 to -0.25; T cell population drops but then recovers slowly. In the blue curve <i>r</i> reduced at 25th iteration from -1 to +0.25 with direction reversal (from–to +), signifying anti-inflammatory cytokine effect supersedes pro-inflammatory cytokine effect.</p
T cell clonal growth in SCT simulations.
<p>A. Individual T cell clone growth simulations accounting for peptide-HLA complex binding affinity and protein of origin tissue expression (IC50/RPKM). Increased T cell frequency (Y-axis) seen if the protein is expressed at a higher level. Different <i>pmHA</i> from a single patient/organ. B. Variable growth pattern of the number of clones in the simulations, number of clones rising over ‘time’ (iterations); T cell clonal growth in response to colonic alloreactive peptides depicted. C. Number of T cell clones after 500 iterations, reflecting the number of high affinity peptides expressed in the tissues studied (GTEX). A non-significant trend towards a larger number of clones in MUD recipients is observed in this graph.</p
Novel and validated loci based on genome-wide association with platelet count and mean platelet volume in COGENT (novel loci are in bold).
*<p>SNPs in locus reaching GWAS significant threshold (5×10<sup>−8</sup>).</p><p>MAF = minor allele frequency; Chr = chromosome; SE = standard error; effect size = age-sex adjusted change in platelet count (10<sup>9</sup> L) or MPV (fL) per copy of minor allele; Maj = major; Min = minor; Het-P = Cochrane Q p-value to assess heterogeneity.</p>#<p>excluding cohorts that were included in the previous study<sup>16</sup> that reported this SNP, the p-value was 8.6×10<sup>−7</sup>.</p
Characteristics of COGENT African-American meta-analysis cohorts.<sup>**</sup>
*<p>All studies are population-based, in addition, JHS has a small group of related individuals.</p>**<p>Mean (SD), and units (untransformed) that were used in the regression models for each trait.</p>***<p>For MPV, complete cohorts of GeneSTAR, HANDLS, and JHS were included, while only a subset of ARIC (n = 644) and Health ABC (n = 182) were included.</p><p>NA = not available; MPV = mean platelet volume.</p